

# Dana-Farber/Harvard Cancer Center

## Note-To-File

---

**RE: DF/HCC Policy Exemption related to COVID-19 Pandemic**

---

This note to file serves to allow for the following temporary policy exemption effective until at least March 1, 2022.

### **RCO-203 Regulatory Documentation Section 5.2.4**

Individuals providing clinical coverage as a result of staffing shortages are not required to be listed on the delegation of authority log. Appropriately trained and delegated research staff must remain accessible remotely and continue to ensure appropriate oversight of research activities. Communication between the covering staff and research team will be appropriately documented and maintained in the research subject file.

Sincerely,

*Jeffrey Meyerhardt*

Electronically signed by:  
Jeffrey Meyerhardt  
Reason: I'm an approver  
Date: Jan 3, 2022 16:44 EST

Jan 3, 2022

*Signature*

*Date*

Jeff Meyerhardt, MD  
DF/HCC Associate Director of Clinical Trials

*Michelle Cox*

Electronically signed by:  
Michelle Cox  
Reason: I'm an approver  
Date: Jan 4, 2022 14:03 EST

Jan 4, 2022

*Signature*

*Date*

Michelle Cox  
Senior Vice President, Research Administration